Pathogenesis of small vessel vasculitis associated with a cytoplasmic antigens: new insights from animal models

Current Opinion in Rheumatology 22, 15-20

DOI: 10.1097/bor.0b013e328332c9e4

Citation Report

#	Article	IF	CITATIONS
1	ANCA-Associated Small Vessel Vasculitis: Clinical and Therapeutic Advances. Current Rheumatology Reports, 2010, 12, 406-413.	2.1	2
2	ANCA Disease. Journal of the American Society of Nephrology: JASN, 2010, 21, 745-752.	3.0	119
3	Neutrophil Elastase, Proteinase 3, and Cathepsin G as Therapeutic Targets in Human Diseases. Pharmacological Reviews, 2010, 62, 726-759.	7.1	676
4	Neutrophils: game changers in glomerulonephritis?. Trends in Molecular Medicine, 2010, 16, 368-378.	3.5	46
5	The Future of ANCA-associated Vasculitis. Rheumatic Disease Clinics of North America, 2010, 36, 609-621.	0.8	8
6	The Systemic Vasculitides. , 2012, , 1720-1727.		O
7	Biomarkers of endothelial cell activation: Candidate markers for drug-induced vasculitis in patients or drug-induced vascular injury in animals. Vascular Pharmacology, 2012, 56, 14-25.	1.0	21
8	Elevated antilysosomal-associated membrane protein-2 antibody levels in patients with adult Henoch-Schönlein purpura. British Journal of Dermatology, 2012, 166, 1206-1212.	1.4	12
9	Involvement of Toso in activation of monocytes, macrophages, and granulocytes. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2593-2598.	3.3	67
10	The Multifaceted Functions of Neutrophils. Annual Review of Pathology: Mechanisms of Disease, 2014, 9, 181-218.	9.6	958
11	Pathophysiological Relationship between Infections and Systemic Vasculitis. Autoimmune Diseases, 2015, 2015, 1-8.	2.7	20